The mTOR Signalling Pathway in Human Cancer

Author： Pópulo Helena   Lopes José Manuel   Soares Paula  

Publisher： MDPI

E-ISSN： 1422-0067|13|2|1886-1918

ISSN： 1422-0067

Source： International Journal of Molecular Sciences, Vol.13, Iss.2, 2012-02, pp. : 1886-1918

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The conserved serine/threonine kinase mTOR (the mammalian target of rapamycin), a downstream effector of the PI3K/AKT pathway, forms two distinct multiprotein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to rapamycin, activates S6K1 and 4EBP1, which are involved in mRNA translation. It is activated by diverse stimuli, such as growth factors, nutrients, energy and stress signals, and essential signalling pathways, such as PI3K, MAPK and AMPK, in order to control cell growth, proliferation and survival. mTORC2 is considered resistant to rapamycin and is generally insensitive to nutrients and energy signals. It activates PKC-α and AKT and regulates the actin cytoskeleton. Deregulation of multiple elements of the mTOR pathway (PI3K amplification/mutation, PTEN loss of function, AKT overexpression, and S6K1, 4EBP1 and eIF4E overexpression) has been reported in many types of cancers, particularly in melanoma, where alterations in major components of the mTOR pathway were reported to have significant effects on tumour progression. Therefore, mTOR is an appealing therapeutic target and mTOR inhibitors, including the rapamycin analogues deforolimus, everolimus and temsirolimus, are submitted to clinical trials for treating multiple cancers, alone or in combination with inhibitors of other pathways. Importantly, temsirolimus and everolimus were recently approved by the FDA for the treatment of renal cell carcinoma, PNET and giant cell astrocytoma. Small molecules that inhibit mTOR kinase activity and dual PI3K-mTOR inhibitors are also being developed. In this review, we aim to survey relevant research, the molecular mechanisms of signalling, including upstream activation and downstream effectors, and the role of mTOR in cancer, mainly in melanoma.

Related content

mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer

By Wei Feng   Zhang Yandong   Geng Li   Zhang Ping   Wang Guangyi   Liu Yan  

International Journal of Molecular Sciences, Vol. 16, Iss. 2, 2015-02 ,pp. : 3267-3282 (16)

MDPI

Access to resources Recommend Favorite

Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells

By Zi Dan   Zhou Zhi-Wei   Yang Ying-Jie   Huang Lin   Zhou Zun-Lun   He Shu-Ming   He Zhi-Xu   Zhou Shu-Feng  

International Journal of Molecular Sciences, Vol. 16, Iss. 11, 2015-11 ,pp. : 27228-27251 (24)

MDPI

Access to resources Recommend Favorite

The Regulatory Role of MeAIB in Protein Metabolism and the mTOR Signaling Pathway in Porcine Enterocytes

By Tang Yulong   Tan Bie   Li Guangran   Li Jianjun   Ji Peng   Yin Yulong  

International Journal of Molecular Sciences, Vol. 19, Iss. 3, 2018-03 ,pp. : 714-714 (1)

MDPI

Access to resources Recommend Favorite

Capsaicin Induces Autophagy and Apoptosis in Human Nasopharyngeal Carcinoma Cells by Downregulating the PI3K/AKT/mTOR Pathway

By Lin Yu-Tsai   Wang Hung-Chen   Hsu Yi-Chiang   Cho Chung-Lung   Yang Ming-Yu   Chien Chih-Yen  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-06 ,pp. : 1343-1343 (1)

MDPI

Access to resources Recommend Favorite

The Involvement of Mutual Inhibition of ERK and mTOR in PLCγ1-Mediated MMP-13 Expression in Human Osteoarthritis Chondrocytes

By Liu Zejun   Cai Heguo   Zheng Xinpeng   Zhang Bing   Xia Chun  

International Journal of Molecular Sciences, Vol. 16, Iss. 8, 2015-08 ,pp. : 17857-17869 (13)

MDPI

Access to resources Recommend Favorite